|
NatureCell is a biotechnology company focused on regenerative medicine, stem cell therapeutics, and bio-based consumer products. Its primary business segment involves the research, development, and commercialization of autologous adipose-derived stem cell therapies, most notably JointStem for osteoarthritis, which has received RMAT and Breakthrough Therapy designations from the US FDA. The company also develops Vascostem for severe peripheral arterial disease and Buerger's disease, and AstroStem for Alzheimer's disease. Through its subsidiary Nature Cell America Inc., NatureCell conducts US clinical trials for stem cell therapies targeting autism spectrum disorder and critical limb ischemia. The company manufactures and sells stem cell culture media, a key raw material for cell therapy production, and operates a cosmetics division under the Dr.Jucre brand, which utilizes stem cell culture medium as a primary ingredient in skincare products. Additionally, NatureCell produces vegan health beverages, including barley sikhye and fermented red ginseng drinks, sold through domestic retail channels and OEM partnerships. The company is preparing to launch an amniotic stem cell storage service. NatureCell collaborates with Albio and BioStar Stem Cell Technology Research Institute for R&D and clinical development. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage naturecell.co.kr |
| Sector Healthcare | IR page — | |
|
Tags
stem cell therapy, regenerative medicine, osteoarthritis, autism spectrum disorder, cell culture media, cosmeceuticals, health beverages, autologous stem cells, clinical trials, biopharmaceuticals, JointStem, Vascostem, AstroStem, Dr.Jucre, Nature Cell America Inc., Albio, BioStar Stem Cell Technology Research Institute, NatureCell Members, BioStar Shop, Sikhye, Fermented Red Ginseng K, Graviola K
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 1.153T |
| Market cap (USD) | $ 848.399M |
| P/E | -425.55 |
| PEG | — |
| P/BV | 18.31 |
| P/S | 56.21 |
| P/OCF | -169.42 |
| P/FCF | -51.31 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -4.4% |
| ROI | -4.5% |
| ROIC | -4.3% |
| Profit margin | -13.7% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -76.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.735B | 32.334B | 19.351B | 21.252B | 20.354B | 16.72B | 23.072B | 26.715B | 27.215B | 26.788B | 30.554B | 25.355B | 29.208B |
| Net profit | -2.838B | 1.226B | -11.68B | -6.814B | -32.031B | -18.87B | 902.009M | 2.235B | -460.739M | -3.223B | -1.335B | 1.895B | -3.509B |
| Free cash flow | -16.386B | -1.59B | — | -18.659B | — | — | — | — | — | -4.141B | -275.928M | -184.011M | 424.974M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 4.37B | 4.1B | 3.69B | 3.56B | 5.1B | 7.07B | 8.75B | 3.95B | 9.82B | 4.99B |
| ↳ YoY growth | -7.3% | -6.1% | -10.1% | -3.5% | +43.6% | +38.5% | +23.8% | -54.8% | +148.5% | -49.2% |
| ↳ 5y CAGR | -1.1% | -0.9% | +1.6% | +10.1% | +16.4% | +1.4% | +22.5% | -0.5% | ||
| Other receivables (KRW) | 3.19B | 551M | 414M | 2.97B | 2.44B | 2.86B | 12.8B | 518M | — | — |
| Borrowings, current (KRW) | 46M | 2.24B | 2.24B | 2.24B | 11.5B | 0.00 | 24.3B | — | — | — |
| Borrowings, non-current (KRW) | 1.92B | 1.87B | 69M | 23M | — | — | 0.00 | — | — | — |
| Bonds payable (KRW) | 4.32B | 0.00 | 0.00 | — | 7.35B | 0.00 | 24.3B | — | — | — |
| Lease liabilities (KRW) | — | — | 0.00 | 2.32B | 2.7B | 2.54B | 1.21B | 2.31B | 1.78B | 2.8B |
| Cash and deposits (KRW) | 3.45B | 9.04B | 14.9B | 21.2B | 41.5B | 32.6B | 31.3B | 29.9B | 28.4B | 16.8B |
| Intangible assets (KRW) | 5.1B | 2.81B | 2.63B | 3.43B | 3.24B | 3.12B | 2.87B | 2.69B | 2.51B | 2.36B |
| Right-of-use assets (KRW) | — | — | 0.00 | 2.33B | 2.66B | 2.46B | 1.03B | 2.28B | 1.8B | 2.32B |
| Net debt (borrowings + leases - cash) (KRW) | -1.48B | -4.93B | -12.6B | -16.6B | -27.3B | -30B | -5.72B | — | — | — |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | -2.14B | 3.48B | 3.7B | 358M | -5.41B | -10.1B | -14.9B | -2.13B | 1.51B | 157M |
| Purchases of property, plant and equipment (KRW) | -2B | — | — | — | — | — | -3.79B | -6.12B | -3.1B | -16.5B |
| Purchases of intangible assets (KRW) | -4.53B | — | — | — | — | — | -1.86M | -676,800 | -17.9M | -47.5M |
| Change in receivables (cash effect) (KRW) | -2.99B | 2.64B | 910M | -2.54B | -1.3B | -2.37B | -4.2B | 8.22B | — | — |
| Change in inventories (cash effect) (KRW) | -1.59B | 1.16B | 1.56B | 63.3M | -754M | -407M | -887M | -210M | — | — |
| Change in payables (cash effect) (KRW) | 287M | -1.48B | -2.49M | 371M | -395M | 1.27B | 107M | -1.07B | — | — |
| Interest paid (cash effect) (KRW) | -266M | -322M | -170M | -169M | -113M | -66M | -159M | -598M | -161M | -194M |
| Income taxes paid (cash effect) (KRW) | 48.3M | 9.53M | 29.9M | 65M | 5.46M | — | — | -137M | 26.5M | 37.9M |
| Share-based compensation (KRW) | 1.98B | 1.81B | 13.4M | 9.16M | — | — | — | — | — | — |
| Operating cash flow before change in receivables (KRW) | -645M | 837M | 2.79B | 2.9B | -4.11B | -7.78B | -10.7B | -10.4B | — | — |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -8.67B | — | — | — | — | — | -18.7B | -8.25B | -1.61B | -16.4B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | -2.86B | -565M | 3.19B | 841M | -19.2B | -31.5B | -8.33B | -12.5B | 1.28B | -3.04B |
| Comprehensive income to owners (KRW) | — | — | — | — | — | -31.5B | -8.33B | -12.5B | 1.28B | -3.04B |
| Provision for credit losses (KRW) | -44.2M | 42.8M | 267M | -77.6M | 2.01B | -1.03B | -802M | -60.1M | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | 0.7% | 0.7% | 6.1% | 1.5% | 28.5% | 11.8% | 5.1% | 0.5% | — | — |
| Reported | Apr 1, 2019 | Apr 1, 2019 | May 15, 2019 | May 15, 2020 | Mar 19, 2021 | Mar 21, 2024 | Mar 19, 2025 | Mar 19, 2025 | Mar 19, 2025 | Mar 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.



